U.S. markets open in 5 hours 10 minutes

Sage Therapeutics, Inc. (SAGE)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
76.61-0.53 (-0.69%)
At close: 4:00PM EDT

Sage Therapeutics, Inc.

215 First Street
Cambridge, MA 02142
United States
617 299 8380

Full Time Employees298

Key Executives

NameTitlePayExercisedYear Born
Ms. Kimi E. IguchiCFO & Treasurer536.37k2.7M1962
Mr. Michael CloonanChief Operating Officer582.75k2.54M1972
Ms. Anne Marie CookSr. VP, Gen. Counsel & Sec.564.84k2.14M1962
Dr. Jeffrey M. JonasChief Innovation Officer, Chair of the Science & Technology Forum and Director983.77k29.44M1953
Dr. Stephen J. KanesChief Medical Officer580.67k973.02k1965
Mr. Barry E. GreenePres, CEO & DirectorN/AN/A1963
Dr. Heinrich Schlieker Ph.D.Sr. VP of Technical OperationsN/AN/AN/A
Dr. Albert J. RobichaudChief Scientific OfficerN/AN/A1961
Mr. Matthew CalistriVP of Investor RelationsN/AN/AN/A
Ms. Erin E. LancianiSr. VP of People & Organizational StrategyN/AN/A1969
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and generalized anxiety disorders; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Sage Therapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2021 is 9. The pillar scores are Audit: 7; Board: 8; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.